Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
-
Kipps, Thomas J. (UC San Diego Moores Cancer Center)
;
Fraser, Graeme (McMaster University (Canadà)) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Barrientos, Jacqueline C. (Northwell Health Cancer Institute) ;
Barr, Paul M. (University of Rochester) ;
Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ;
O'Brien, Susan M. (University of California) ;
Dilhuydy, Marie-Sarah (Hôpital Haut-Lévêque) ;
Hillmen, Peter (University of Leeds) ;
Jaeger, Ulrich (Medical University of Vienna) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Stilgenbauer, Stephan (University of Ulm) ;
Chanan-Khan, Asher A. (Mayo Clinic Cancer Center) ;
Mahler, Michelle (Janssen Research and Development) ;
Salman, Mariya (Janssen Research and Development) ;
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Balasubramanian, Sriram (Janssen Research and Development) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Londhe, Anil (Janssen Research and Development) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research and Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Hallek, Michael (University of Cologne) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
